Nilontinib induced keratosis pilaris atrophicans

A 46-year-old man with chronic myelogenous leukemia developed keratosis pilaris-like symptoms, including red bumps and patchy hair loss, after starting nilotinib, a second-generation tyrosine kinase inhibitor. Cutaneous reactions are common non-hematologic side effects of nilotinib, but it was crucial to differentiate these from more severe drug hypersensitivity reactions that might require stopping the medication. Proper classification of skin eruptions based on their morphology, rather than broadly categorizing them as "chemotherapy eruptions," was emphasized for better management of these adverse effects.